Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2016 · 10-Q
Revenue$21.62M$21.62M+22.1% vs Q3 2015 Net Income$1.05M$1.05M−99.5% vs Q3 2015 EPS Diluted$0.05$0.05−99.5% vs Q3 2015 Operating Income$5,466,000−36.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$17,761,000+70.2% Margins · derivedOperating margin25.3%−23.3 pt vs Q3 2015
Net margin4.9%
ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end